Cooling Adjunct for Nasal Medications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nasal congestion and rhinitis, such as intranasal steroids and menthol, have limited efficacy and patient adherence issues due to side effects, slow onset of action, and lack of immediate relief, particularly for allergic rhinitis and rhinosinusitis.
Innovation Solution
The use of 1-[Dialkyl-phosphinoyl]-alkane compounds, like DIPA-1-8 and DIPA-1-9, as a combination with existing nasal medications to provide immediate and long-lasting relief of nasal congestion through a refreshing cooling sensation, enhancing patient adherence and compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intranasal steroids are used to treat nasal congestion, then anti-inflammatory effect is improved, but onset of action is slow and patient adherence is reduced
Solution Approach 1:
The patent combines intranasal steroids with cooling agents (menthol, eucalyptus oil, camphor) in a single composition. The cooling agents provide immediate symptomatic relief of nasal congestion through TRPM8 receptor activation, while the steroids provide anti-inflammatory effects. This merging resolves the contradiction by delivering both fast-acting and long-term therapeutic effects simultaneously, improving patient adherence through immediate relief.
2Loss of time
If menthol is used to provide cooling sensation, then immediate relief is improved, but therapeutic efficacy for inflammation is limited
Solution Approach 1:
The patent merges menthol (providing immediate cooling relief via TRPM8 activation) with intranasal steroids (providing anti-inflammatory therapeutic efficacy). The composition delivers both functions simultaneously: menthol addresses immediate nasal congestion symptoms while steroids treat the underlying inflammation, resolving the contradiction between speed of relief and therapeutic effectiveness.
3Reliability
If existing nasal medications are used, then treatment is provided, but patient satisfaction and adherence are reduced due to lack of immediate relief
Solution Approach 1:
The patent combines medications with proven therapeutic effects (steroids, antihistamines) with cooling agents (menthol, eucalyptus oil, camphor) that provide immediate symptomatic relief. This merging creates a dual-action formulation that satisfies both therapeutic needs and patient desires for quick relief, thereby improving adherence and satisfaction without compromising treatment reliability.
4Ease of operation
If cooling agents are added to nasal medications, then patient adherence is improved, but composition complexity increases
Solution Approach 1:
The patent merges multiple active ingredients (steroids, antihistamines, cooling agents) into a single intranasal composition delivered by a unified spray device. This integration simplifies patient use (improving adherence) while managing complexity through formulation science and single-device delivery, resolving the contradiction between enhanced adherence and composition complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds offer rapid, robust, and penetrating relief from nasal congestion, improving patient satisfaction and adherence to treatment regimens by providing immediate and sustained benefits when used with intranasal steroids or antihistamines.
Implementation Method 1
Chemical sensory/cooling agents are molecules that can mimic the sensations of heat abstraction without a change in tissue temperatures. The compounds act on cold-sensing ion channels (e.g., TRPM8) in the nasal mucosa
Data Source
AI summary
The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-alkyl-phosphinoyl-alkanes as described herein, DIPA-1-8 and DIPA-1-9, and 2-6 and 2-7 that are collectively referred to herein as “DAPA compounds”, that are useful in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by inflammation, irritation, itch, or pain) in the nasal cavity. The applicant has found that localized delivery of DAPA compounds in combination with an intranasal steroid or an intranasal antihistamine immediately relieves nasal discomfort and enhances patient adherence to the use of the nasal medications.